Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 7/20 | 0.46 |
| ▸ | FLT3 | P36888 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081802 | 0.90 | FLT3 (0.43) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4092903 | 0.87 | ABL1 (0.61) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4093502 | 0.87 | ABL1 (0.63) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4089596 | 0.86 | FLT3 (0.49) | AURKAKITFLT3KDRFLT1 | |
| SCHEMBL4083868 | 0.86 | ABL1 (0.59) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4082917 | 0.84 | AURKA (0.48) | AURKAABL1BCRFLT3MEN1 | |
| SCHEMBL4091567 | 0.84 | AURKA (0.48) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4081436 | 0.83 | AURKA (0.57) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4081942 | 0.83 | KIT (0.54) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL4088217 | 0.83 | AURKA (0.51) | AURKAABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2058315-A1 | 1H-Furo[3,2-C]Pyrazoles active as aurora kinase inhibitors | Nerviano Medical Sciences S.r.l. (IT) | 2009-05-13 | — | — | EP | disclosed |